Stock YPH ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Market Closed - Deutsche Boerse AG
Other stock markets
 14:49:28 17/05/2024 BST 		5-day change 1st Jan Change
8.472 EUR -3.73% Intraday chart for Astellas Pharma Inc. -3.75% -22.84%
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
05-08 Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company is one of the best yield companies with high dividend expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 139.52 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ASTELLAS PHARMA INC. Stock Astellas Pharma Inc.
-22.84% 17.15B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 693B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 584B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 372B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.39% 294B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 211B
A+
NOVARTIS AG Stock Novartis AG
+10.02% 210B
B-
AMGEN INC. Stock Amgen Inc.
+8.49% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. YPH Stock
  5. Ratings Astellas Pharma Inc.